Alert: Rating Downgrade (12/15/23)-Acadia Pharmaceuticals Inc (NASDAQ: ACAD).


Stock Rating Downgrade

In the last week the Value Trend Rating for Acadia Pharmaceuticals Inc (NASDAQ: ACAD) weakened from C to D reflecting eroding fundamentals and low Appreciation Potential.


Recent Price Action

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stock increased 1.9% on 12/15/23. The shares closed at $28.58. Moreover, exceptionally high trading volume at 267% of normal accompanied the advance. The stock has been strong relative to the market over the last nine months and has risen 31.2% during the last week.

Current PriceTarget Research Rating

Reflecting future returns on capital that are forecasted to exceed the cost of capital, ACAD is expected to be a major Value Builder.

Acadia Pharmaceuticals has a current Value Trend Rating of D (Negative). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Acadia Pharmaceuticals has a very low Appreciation Score of 6 but a good Power Rating of 80, and the Negative Value Trend Rating results.

Be the first to comment

Leave a Reply

Your email address will not be published.